MCK Stock Recent News
MCK LATEST HEADLINES
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the third quarter of fiscal 2025 despite ongoing macroeconomic challenges. The company also raised its full-year guidance.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
McKesson's third-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson Corporation. (NYSE:MCK ) Q3 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Rachel Rodriguez - VP of Investor Relations Brian Tyler - Chief Executive Officer Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Eric Percher - Nephron Research Kevin Caliendo - UBS Allen Lutz - Bank of America Brian Tanquilut - Jefferies Lisa Gill - JPMorgan Stephen Baxter - Wells Fargo Erin Wright - Morgan Stanley George Hill - Deutsche Bank Daniel Grosslight - Citi Operator Welcome to McKesson's Third Quarter Fiscal 2025 Earnings Conference Call.
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
McKesson (MCK) came out with quarterly earnings of $8.03 per share, missing the Zacks Consensus Estimate of $8.04 per share. This compares to earnings of $7.74 per share a year ago.
Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its U.S. pharmaceutical segment, which includes branded and specialty drugs.
Healthcare distribution and services specialist McKesson (MCK 0.59%) reported mixed financial results for fiscal 2025's third quarter on Wednesday, Feb. 5. McKesson beat earnings expectations with an adjusted EPS of $8.03, coming in just ahead of the projected $8.01.